Meeker David P sold $5.1M of RYTM
Meeker David P (President and CEO) sold 50,000 shares of RHYTHM PHARMACEUTICALS, INC. (RYTM) at an average of $102.67 ($101.75–$105.19, $5.13M total) across 5 trades on 2026-09-14 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The main tradable implication is sentiment and positioning around insider activity. Because the sale is under a pre-arranged 10b5-1 plan, it is less likely to indicate new, material negative information.
Market read
A C-suite insider sold ~$5.13M of stock on 2026-09-14; traders may monitor for any additional insider activity or fundamental updates.
What to watch
Consider whether the CEO’s post-sale holdings (239,258 shares) remain substantial and whether there are any concurrent operational or clinical catalysts not mentioned in the filing.
Background
This is an SEC Form 4 insider transaction by the company’s President and CEO, reported as an open-market sale executed across five trades on 2026-09-14.
Ticker impact
Rhythm Pharmaceuticals CEO David P. Meeker sold about 50,000 shares on 2026-09-14 for ~$5.13M under a pre-arranged 10b5-1 plan.
Likely limited, short-lived sentiment impact; watch for follow-through selling pressure only if additional insider sales or negative fundamentals emerge.
Form 4 shows a large dollar amount (~$5.13M) and C-suite role, but the presence of a pre-arranged 10b5-1 plan reduces the signal of new negative information.
Market effects
No direct sector read-through; this is company-specific insider transaction information.
None.
None.
Counterpoint
10b5-1 sales often reflect routine liquidity planning rather than bearish expectations, so the market may overreact if it treats it as a fresh negative signal.
Key entities
- issuerRhythm Pharmaceuticals, Inc.
US-listed company whose CEO filed the Form 4 insider sale.
- insiderDavid P. Meeker
President and CEO who sold shares under a pre-arranged 10b5-1 plan.
